Structural study on mutant alpha-L-iduronidases: insight into mucopolysaccharidosis type I.
To elucidate the basis of mucopolysaccharidosis type I (MPS I), we constructed structural models of mutant alpha-L: -iduronidases (IDUAs) resulting from 33 amino acid substitutions that lead to MPS I (17 severe, eight intermediate, and eight attenuated). Then, we examined the structural changes in the enzyme protein by calculating the number of atoms affected and determined the root-mean-square distance (RMSD) and the solvent-accessible surface area (ASA). In the severe MPS I group, the number of atoms influenced by a mutation and the average RMSD value were larger than those in the attenuated group, and the residues associated with the mutations identified in the severe group tended to be less solvent accessible than those in the attenuated group. The clinically intermediate phenotype group exhibited intermediate values for the numbers of atoms affected, RMSD, and ASA between those in the severe group and those in the attenuated group. The results indicated that large structural changes had occurred in the core region in the severe MPS I group and small ones on the molecular surface in the attenuated MPS I group. Color imaging revealed the distributions and degrees of the structural changes caused by representative mutations for MPS I. Thus, structural analysis is useful for elucidating the basis of MPS I. As there was a difference in IDUA structural change between the severe MPS I group and the attenuated one, except for a couple of mutations, structural analysis can help predict the clinical outcome of the disease.
Sugawara
Kanako
K
Department of Analytical Biochemistry, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo, 204-8588, Japan.
Saito
Seiji
S
Graduate School of Agricultural and Life Science, The University of Tokyo, Tokyo, Japan.
Ohno
Kazuki
K
Center for Biological Resources and Informatics, Tokyo Institute of Technology, Yokohama, Japan.|Drug Discovery Research, Astellas Pharm Inc, Tsukuba, Japan.
Okuyama
Torayuki
T
Department of Clinical Laboratory Medicine, National Center for Child Health and Development, Tokyo, Japan.
Sakuraba
Hitoshi
H
Department of Analytical Biochemistry, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo, 204-8588, Japan. sakuraba@my-pharm.ac.jp.
D019943:Amino Acid Substitution / Q000235:genetics*; D006801:Humans; D007068:Iduronidase / Q000737:chemistry* / Q000235:genetics* / Q000502:physiology; D008958:Models, Molecular; D008059:Mucopolysaccharidosis I / Q000201:enzymology / Q000235:genetics*; D020125:Mutation, Missense
D007068:Iduronidase